{{Rsnum
|rsid=2279115
|Gene=BCL2
|Chromosome=18
|position=63319604
|Orientation=minus
|GMAF=0.4458
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=BCL2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 0.0 | 0.0 | 0.0
| HCB | 22.2 | 42.2 | 35.6
| JPT | 13.6 | 59.1 | 27.3
| YRI | 1.6 | 19.0 | 79.4
| ASW | 0.0 | 0.0 | 0.0
| CHB | 22.2 | 42.2 | 35.6
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID|19237173}} [[prostate cancer]] treatment response [[rs2279115]] and [[rs7121]]

{{PMID Auto
|PMID=19276283
|Title=Interaction between BCL2 and Interleukin-10 Gene Polymorphisms Alter Outcomes of Diffuse Large B-Cell Lymphoma following Rituximab Plus CHOP Chemotherapy
}}
{{PMID Auto
|PMID=19520430
|Title=BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients
}}

{{PMID Auto
|PMID=22568453
|Title=Association of CASP3 polymorphism with hematologic toxicity in advanced NSCLC patients treated with platinum-based chemotherapy
}}
{{PMID Auto
|PMID=19390575
|Title=Lung cancer susceptibility model based on age, family history and genetic variants.
|OA=1
}}

{{PMID Auto
|PMID=19539330
|Title=The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.
}}

{{PMID Auto
|PMID=24321200
|Title=Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}